Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology SA (CYAD) is a biotechnology company headquartered in Mont‑Saint‑Guibert, Belgium, with shares admitted to trading on Euronext. Its regulatory news flow provides detailed insight into the company’s strategic focus on managing and licensing its intellectual property portfolio, including proprietary technology platforms, as well as its capital structure and major shareholdings.
News about Celyad Oncology frequently covers decisions that affect its operational profile and financial position. For example, the company has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources, stating that it will concentrate on the management and licensing of its intellectual property portfolio. Other releases describe the divestiture of its research facility’s equipment and office furniture under an asset purchase agreement, which management expects to extend the company’s cash runway.
Investors following CYAD news can also track financing transactions and ownership changes. The company has reported a private placement financing with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, and has issued multiple transparency notifications detailing when this shareholder has crossed voting‑rights thresholds. In addition, Celyad Oncology regularly publishes updates on the total number of shares and voting rights, including the impact of double voting rights on certain registered shares.
This news page is useful for readers who want to monitor regulatory announcements on Celyad Oncology’s strategic decisions, capital increases, asset sales, major shareholdings and voting‑rights structure. By reviewing these updates, users can follow how the company’s focus on intellectual property, its financing arrangements and its ownership profile evolve over time.
Celyad Oncology (CYAD) received a Bid Price Notice from Nasdaq on April 19, 2023, indicating its American Depositary Shares (ADSs) were below the $1.00 minimum closing bid price for 30 consecutive business days. The Company has until October 16, 2023, to regain compliance by maintaining a price of at least $1.00 for ten consecutive days. If compliance is not achieved, the ADSs may be transferred to Nasdaq Capital Market or subjected to delisting. Additionally, on March 31, 2023, Celyad received a Stockholders’ Equity Notice from Nasdaq for not meeting the $10 million stockholders’ equity requirement, reporting approximately $4.6 million as of December 31, 2022. The Company has until May 15, 2023, to submit a compliance plan. Despite these notices, Celyad states that its business operations remain unaffected.
Celyad Oncology (Euronext & Nasdaq: CYAD) received a notice from Nasdaq on
Celyad Oncology (CYAD) announces the appointment of Georges Rawadi as the new CEO, effective March 23, 2023. Rawadi, a seasoned executive with 20+ years in pharma/biotech, has previously held significant roles within Celyad and other biotech firms. He will officially start on April 17, 2023, while Michel Lussier remains as Interim CEO until then. The Board has expressed confidence in Rawadi's leadership abilities and his expertise in CAR-T therapies to drive growth and development. Rawadi emphasizes his commitment to harnessing Celyad's intellectual property to overcome limitations in CAR-T approaches.
Celyad Oncology (CYAD) announced a shift in strategy focused on enhancing CAR-T therapies through its research on NKG2D, B7-H6, and shRNA platforms. The company reported a net loss of €40.9 million for 2022, an increase compared to €26.5 million in 2021, primarily due to a €35.1 million impairment of oncology intangible assets. As of December 31, 2022, Celyad had cash reserves of €12.4 million, projected to fund operations into Q4 2023, but anticipates needing additional financing within the next 12 months. Upcoming milestones include updates on research platforms and the introduction of a new CEO in 2023.
Celyad Oncology (Euronext & Nasdaq: CYAD) announced it will release its full year 2022 financial results on March 23, 2023. A conference call is scheduled for March 24, 2023, at 1 p.m. CET / 8 a.m. ET. Company management will discuss the results and provide updates on recent changes and milestones. Participants can join via various telephone options or access a live webcast. Celyad specializes in developing innovative CAR T-cell therapies. The company emphasizes its strategic model and the potential of its IP, while also highlighting risks including uncertainties about its ability to continue as a going concern and potential patent disputes.
Celyad Oncology (CYAD) announced a non-cash impairment of €20.5 million in goodwill and €35.1 million in consolidated intangible assets for the fiscal year ending December 31, 2022. This impairment results from a strategic shift emphasizing R&D and monetization of intellectual property due to uncertainty in deal flow. The company's net assets have fallen below half of its capital, prompting the Board to propose a business plan at the May 5, 2023 shareholders' meeting. An audit for fiscal year 2022 is still in process, with detailed results expected around March 23, 2023.
Celyad Oncology reported notable challenges in its 2022 operations, impacting its clinical development efforts. Key issues included insufficient efficacy results from the CYAD-211 program in the IMMUNICY-1 trial and serious adverse events in the CYAD-101 trial, prompting temporary suspensions. In response, the company implemented significant cost-cutting measures, executed a hiring freeze, and transferred employees to external partners to streamline operations. These transformations are projected to extend the cash runway until Q4 2023 without external financing. Celyad will now focus on enhancing its research and maximizing its intellectual property estate.
Celyad Oncology (NASDAQ: CYAD) faced significant challenges in 2022, leading to a strategic transformation. Clinical trials for its allogeneic CAR-T therapies, CYAD-211 and CYAD-101, encountered issues with efficacy and safety, resulting in a temporary suspension of trials. Consequently, the board decided to refocus on core assets and undergo organizational restructuring. Initiatives included cost-cutting measures, a hiring freeze, and asset sales. These actions are projected to extend the cash runway until Q4 2023. Looking ahead, the company aims to strengthen its research in NKG2D and B7-H6 platforms, optimize its intellectual property, and foster strategic collaborations.
Celyad Oncology faced significant challenges in 2022, including insufficient clinical efficacy in its allogeneic CAR-T programs, leading to a temporary suspension of trials. The company's board decided to focus on core assets and restructure its operations. Key measures included cost-cutting initiatives, a hiring freeze, and organizational transfers to ProPharma Group. These efforts are projected to extend the cash runway into Q4 2023. Celyad also initiated a reorganization under interim CEO Michel Lussier, concentrating on its research in NKG2D and B7-H6 while maximizing its intellectual property. The goal is to create shareholder value through strategic collaborations.
Celyad Oncology (Euronext & Nasdaq: CYAD) announced the publication of data from the THINK study in The Lancet Haematology, evaluating CYAD-01, an autologous CAR T-cell therapy for relapsed or refractory acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). The Phase 1 study involved 16 patients and demonstrated favorable safety and clinical activity, with three of 12 evaluable patients achieving an objective response. Notably, this is among the first studies using multiple infusions of CAR T-cell therapy without preconditioning chemotherapy, addressing the challenging treatment landscape for older patients with r/r AML/MDS.